ABUS - Arbutus Biopharma Corp

4.31
-0.080   -1.856%

Share volume: 1,025,859
Last Updated: 05-12-2026
Pharmaceutical Products/Pharmaceutical Preparations: 0.10%

PREVIOUS CLOSE
CHG
CHG%
$4.39
-0.08
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 25%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.69%
1 Month
-1.37%
3 Months
8.29%
6 Months
-5.48%
1 Year
35.11%
2 Year
49.13%
Key data
Stock price
$4.31
P/E Ratio 
N/A
DAY RANGE
$4.24 - $4.38
EPS 
-$0.17
52 WEEK RANGE
$2.94 - $5.10
52 WEEK CHANGE
$36.39
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
195.478 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-01-2025
BETA 
-0.51
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$836,440
AVERAGE 30 VOLUME 
$1,828,323
Company detail
CEO: William H. Collier
Region: US
Website: arbutusbio.com
Employees: 90
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Arbutus Biopharma Corporation develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate. AB-836, an oral capsid inhibitor that suppresses HBV DNA replication, is in Phase Ia/Ib clinical trial targeted to hepatocytes.

Recent news